LAG3 is the most promising immune checkpoint next to PD-1 and CTLA-4. High LAG3 and
FGL1 expression boosts tumor growth by inhibiting the immune microenvironment. This …

Immune checkpoint therapy has achieved significant efficacy by blocking inhibitory
pathways to release the function of T lymphocytes. In the clinic, anti-programmed cell death …

Background This study investigated the role of fibrinogen-like protein 1 (FGL1) in regulating
gefitinib resistance of PC9/GR non-small cell lung cancer (NSCLC). Methods The effect of …

Fibrinogen-associated protein (FREP) family is a family of proteins with a fibrin domain at the
carboxyl terminus. Recent investigations illustrated that two members of FREP family …

Abstract Fibrinogen-like protein 1 (FGL1) is a novel hepatokine that forms part of the
fibrinogen superfamily. It is predominantly expressed in the liver under normal physiological …

The protective role of fibrinogen-like-protein 1 (FGL1) in liver injury has been reported
previously. However, there are few studies on FGL1 expression in gastric cancer (GC) …

Despite liver cancer being the second-leading cause of cancer-related death worldwide, few
systemic drugs have been approved. Sorafenib, the first FDA-approved systemic drug for …

Simple Summary Cancer remains a serious health problem owing to its high morbidity and
mortality. Immunotherapy, represented by anti-programmed death-1D1/anti-PD-Ligand 1 …

Although the role of fibrinogen-like protein 1 (FGL1) in tumorigenesis is well known, a pan-
cancer analysis of FGL1 lacks. We used bioinformatics techniques to analyze cancer data …

Hepatocellular carcinoma (HCC) is an aggressive malignancy with limited effective
treatments and ranks as the second most lethal tumor. Immunotherapy has brought great …